Form 4: Vera Therapeutics CLO Sells Shares for Tax Obligations

Vera Therapeutics' Chief Legal Officer, Jason S. Carter, sold 3,864 shares of Class A Common Stock to cover tax withholding obligations.

Summary

• Jason S. Carter, Chief Legal Officer of Vera Therapeutics, Inc. (VERA), reported a sale of company stock.
• The transaction involved the disposition of 3,864 shares of Class A Common Stock.
• The shares were sold on November 21, 2025, at a weighted-average price of $27.8204 per share.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Carter beneficially owns 49,136 shares of Class A Common Stock.
• The sale was executed pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction primarily for tax withholding purposes related to vested restricted stock units, rather than a discretionary sale based on market outlook or company performance.

Positives

• The transaction indicates the vesting of restricted stock units, which often signifies the achievement of performance milestones or tenure by the Chief Legal Officer.

Negatives

• The sale results in a slight reduction in the direct beneficial ownership of company stock by a key executive, which could be perceived as a minor decrease in insider alignment, although it is a routine tax-related event.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction filing (Form 4) and does not provide specific insights into broader industry trends or competitive landscape. It reflects standard executive compensation practices within the biotechnology or pharmaceutical sector, where restricted stock units are a common form of equity compensation.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but generally viewed as a routine event for tax purposes, unlikely to significantly impact shareholder confidence.
• Employees: The vesting of RSUs and subsequent tax-related sale is a standard part of executive compensation, reflecting normal compensation processes.

Key Dates

Keywords

Vera Therapeutics, VERA, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation, Jason S Carter